Vident Investment Advisory’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-2,994
| Closed | -$695K | – | 1280 |
|
|
2022
Q1 | $695K | Buy |
2,994
+492
| +20% | +$114K | 0.02% | 822 |
|
|
2021
Q4 | $986K | Sell |
2,502
-1,552
| -38% | -$612K | 0.03% | 712 |
|
|
2021
Q3 | $1.81M | Sell |
4,054
-290
| -7% | -$130K | 0.05% | 472 |
|
|
2021
Q2 | $1.69M | Buy |
4,344
+1,634
| +60% | +$635K | 0.05% | 474 |
|
|
2021
Q1 | $973K | Sell |
2,710
-14
| -0.5% | -$5.03K | 0.03% | 616 |
|
|
2020
Q4 | $1.34M | Buy |
+2,724
| New | +$1.34M | 0.05% | 449 |
|
|
2020
Q2 | – | Sell |
-3,662
| Closed | -$779K | – | 841 |
|
|
2020
Q1 | $779K | Sell |
3,662
-229
| -6% | -$48.7K | 0.05% | 464 |
|
|
2019
Q4 | $1.6M | Buy |
3,891
+1,328
| +52% | +$547K | 0.1% | 317 |
|
|
2019
Q3 | $905K | Sell |
2,563
-73
| -3% | -$25.8K | 0.08% | 188 |
|
|
2019
Q2 | $1.33M | Buy |
2,636
+1,186
| +82% | +$596K | 0.11% | 134 |
|
|
2019
Q1 | $1.44M | Sell |
1,450
-38
| -3% | -$37.8K | 0.08% | 355 |
|
|
2018
Q4 | $1.29M | Sell |
1,488
-572
| -28% | -$497K | 0.07% | 364 |
|
|
2018
Q3 | $2.13M | Sell |
2,060
-137
| -6% | -$142K | 0.08% | 312 |
|
|
2018
Q2 | $2.02M | Sell |
2,197
-2,515
| -53% | -$2.31M | 0.08% | 324 |
|
|
2018
Q1 | $4.56M | Buy |
4,712
+1,280
| +37% | +$1.24M | 0.19% | 77 |
|
|
2017
Q4 | $1.55M | Sell |
3,432
-305
| -8% | -$138K | 0.07% | 310 |
|
|
2017
Q3 | $1.55M | Buy |
3,737
+113
| +3% | +$46.7K | 0.08% | 309 |
|
|
2017
Q2 | $1.27M | Buy |
3,624
+1,397
| +63% | +$489K | 0.11% | 298 |
|
|
2017
Q1 | $1.14M | Buy |
2,227
+371
| +20% | +$191K | 0.11% | 295 |
|
|
2016
Q4 | $659K | Buy |
1,856
+547
| +42% | +$194K | 0.08% | 321 |
|
|
2016
Q3 | $700K | Sell |
1,309
-6
| -0.5% | -$3.21K | 0.09% | 316 |
|
|
2016
Q2 | $740K | Sell |
1,315
-372
| -22% | -$209K | 0.1% | 303 |
|
|
2016
Q1 | $802 | Buy |
1,687
+787
| +87% | +$374 | 0.05% | 358 |
|
|
2015
Q4 | $594K | Buy |
+900
| New | +$594K | 0.08% | 351 |
|